Ribociclib
- Generic Name
- Ribociclib
- Brand Names
- Kisqali 200 Mg Daily Dose Carton, Kisqali Femara Co-pack, Kisqali
- Drug Type
- Small Molecule
- Chemical Formula
- C23H30N8O
- CAS Number
- 1211441-98-3
- Unique Ingredient Identifier
- TK8ERE8P56
- Background
Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring tha...
- Indication
用于联合芳香酶抑制剂或氟维司群治疗激素受体(HR)阳性、人表皮生长因子受体2(HER2)阴性的晚期或转移性乳腺癌成人患者。
- Associated Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer
- Associated Therapies
- -
A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)
- First Posted Date
- 2017-11-28
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 19
- Registration Number
- NCT03355794
- Locations
- 🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸Levine Cancer Institute, Charlotte, North Carolina, United States
Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC
- Conditions
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 105
- Registration Number
- NCT03333343
- Locations
- 🇨🇳
Novartis Investigative Site, Taipei, Taiwan
Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer
- First Posted Date
- 2017-09-27
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 33
- Registration Number
- NCT03294694
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer
- First Posted Date
- 2017-09-18
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT03285412
- Locations
- 🇺🇸
Mass General/North Shore Cancer Center, Danvers, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer.
- Conditions
- Interventions
- First Posted Date
- 2017-08-14
- Last Posted Date
- 2021-03-17
- Lead Sponsor
- SOLTI Breast Cancer Research Group
- Target Recruit Count
- 106
- Registration Number
- NCT03248427
- Locations
- 🇪🇸
Centro Oncológico MD Anderson International España, Madrid, Spain
🇪🇸Hospital General de Catalunya, Barcelona, Spain
🇪🇸Hospital Clinic de Barcelona, Barcelona, Spain
Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2017-08-02
- Last Posted Date
- 2023-01-05
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 43
- Registration Number
- NCT03237390
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic Hospital, Phoenix, Arizona, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Impact of Ribociclib on Head and Neck Squamous Cell Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-06-07
- Last Posted Date
- 2019-02-25
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT03179956
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)
- Conditions
- Interventions
- First Posted Date
- 2017-04-14
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 48
- Registration Number
- NCT03114527
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
A Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma
- First Posted Date
- 2017-03-30
- Last Posted Date
- 2017-10-25
- Lead Sponsor
- Assaf-Harofeh Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT03096912
- Locations
- 🇮🇱
Assaf Harofeh Medical Center, Be'er Ya'aqov, Israel
Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-03-30
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 502
- Registration Number
- NCT03096847
- Locations
- 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.